Johnson & Johnson's (JNJ) "Buy" Rating Reiterated at Guggenheim

Key Points

• Guggenheim reiterated a “Buy” rating on Johnson & Johnson with a $287 price target, implying 11.76% potential upside. Analysts overall rate the stock a “Moderate Buy,” with an average target of $276.22.
• Johnson & Johnson exceeded quarterly expectations, reporting $2.90 in EPS versus the $2.84 consensus and $25.31 billion in revenue, up 6.6% year over year. Management provided fiscal 2026 EPS guidance of $11.60–$11.75.
• Key risks include future patent expirations and MedTech pressure, while insiders sold more than $23 million of stock in the past 90 days. Investors are also watching whether pharmaceutical growth can offset competition and weakness in parts of the MedTech business.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock had its "buy" rating restated by Guggenheim in a note issued to investors on Wednesday, Benzinga reports. They presently have a $287.00 price objective on the stock. Guggenheim's target price points to a potential upside of 11.76% from the company's current price.

Several other equities analysts have also recently weighed in on the company. Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. Johnson Rice restated a "buy" rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Royal Bank Of Canada boosted their target price on Johnson & Johnson from $287.00 to $290.00 and gave the stock an "outperform" rating in a research report on Tuesday. Wells Fargo & Company boosted their target price on Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Finally, Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $276.22.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $256.81 on Wednesday. The firm has a market cap of $618.87 billion, a PE ratio of 29.67, a PEG ratio of 2.48 and a beta of 0.21. The stock's fifty day moving average price is $265.86 and its two-hundred day moving average price is $248.63. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business's revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.54 EPS for the current year.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 87,569 shares of company stock valued at $23,064,544 in the last ninety days. Corporate insiders own 0.16% of the company's stock.

Hedge Funds Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently modified their holdings of the business. Mallini Complete Financial Planning LLC grew its position in Johnson & Johnson by 5.6% during the 3rd quarter. Mallini Complete Financial Planning LLC now owns 974 shares of the company's stock worth $258,000 after acquiring an additional 52 shares during the last quarter. Congress Asset Management Co. lifted its holdings in Johnson & Johnson by 599.6% during the 3rd quarter. Congress Asset Management Co. now owns 37,492 shares of the company's stock worth $9,926,000 after buying an additional 32,133 shares during the period. Colton Groome Financial Advisors LLC raised its stake in Johnson & Johnson by 219.1% during the 3rd quarter. Colton Groome Financial Advisors LLC now owns 7,145 shares of the company's stock worth $1,892,000 after buying an additional 4,906 shares during the period. Eleva Capital SAS acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $1,442,000. Finally, Baker Tilly Wealth Management LLC raised its stake in Johnson & Johnson by 4.7% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 10,423 shares of the company's stock worth $2,759,000 after buying an additional 469 shares during the period. Institutional investors own 69.55% of the company's stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: RBC maintains a Buy rating: RBC Capital Markets continues to support JNJ, citing acceleration in the Innovative Medicine segment. The analyst view suggests pharmaceutical momentum may offset ongoing weakness and competition in MedTech. RBC Capital Keeps Their Buy Rating on Johnson & Johnson
• Positive Sentiment: ICOTYDE data strengthens the pipeline: Two-year Phase 3 results showed Johnson & Johnson’s once-daily oral psoriasis treatment maintained skin clearance and consistent safety through Week 112. The data support ICOTYDE’s potential as a differentiated treatment for difficult-to-treat psoriasis and improve confidence in JNJ’s replacement-product strategy. Long-Term Psoriasis Data for ICOTYDE
• Positive Sentiment: Defensive dividend appeal remains intact: Several investment articles continue to present JNJ as a reliable, recession-resistant Dividend King, supported by diversified pharmaceutical, medical-device and consumer-health exposure. This may attract investors seeking stability amid broader market concerns. Johnson & Johnson as a Defensive Dividend Stock
• Neutral Sentiment: MedTech performance is a key near-term test: Analysts expect Vision, Orthopedics and Surgery to potentially improve after a second-quarter slowdown, but Abiomed-related and competitive pressures remain. J&J MedTech Rebound Analysis
• Negative Sentiment: Patent-cliff and earnings risks remain: Investors are looking ahead to the October 13 earnings report and are concerned that a roughly $4 billion 2027 patent expiration could pressure future revenue. Current valuation also leaves less room for disappointment if results or guidance fall short. Johnson & Johnson Patent Cliff Analysis

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.